Guggenheim lowered the firm’s price target on Cryoport (CYRX) to $10 from $11 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for several companies in its Diagnostics and Life Sciences Tools coverage to reflect recent updates from the companies after meetings with management teams.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYRX:
- Cryoport upgraded to Buy from Neutral at UBS
- CryoPort’s Mixed Performance and Sector Uncertainties Justify Hold Rating
- CryoPort’s Stabilization Amid Market Uncertainties: A Hold Rating Analysis
- CryoPort’s Strong Performance and Strategic Positioning Earns Buy Rating from Analyst
- CryoPort Inc’s Earnings Call: Strong Growth and Optimism
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue